GKGerald L. Klein

Gerald L. Klein

*This is an algorithmically generated author record based on publicly available information.

Gerald L. Klein has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    More Physicians and Dentists Should Participate in Clinical Trials Now!

    by Gerald L Klein, Marion Stamp-Cole, Freddyq Byrth, Gail Brown, Patrick Loebs, Roger E Morgan, Kenny Carberry, Alexandre Vieira

    Clinical trials offer physicians and dentists meaningful opportunities to expand patient care, strengthen professional relevance, and contribute directly to scientific progress. Many patients, particularly those with chronic, progressive, rare, or treatment‑resistant conditions, exhaust standard therapies and may benefit from investigational options available only through research. By participating in clinical trials, clinicians might provide access to emerging therapies, diagnostics, devices, and care strategies while allowing patients to remain within their trusted community practices. Beyond patient benefit, clinical trial involvement may enhance professional identity by positioning clinicians as contributors to evidence generation rather than solely consumers of it. Participation may increase referrals, assist in elevating a practice’s reputation, and create opportunities for scholarly collaboration, including publications and conference presentations. When properly structured, research may also provide legitimate financial value through study budgets that offset investigator time, staff effort, and protocol‑required procedures. Engagement in clinical research potentially exposes clinicians to new scientific developments earlier, offering a dynamic form of continuing education that may help keep their practice intellectually stimulating. For many, research participation renews professional purpose and may help mitigate burnout by reconnecting daily work to discovery, teamwork, and broader contributions to patient care. As healthcare moves toward precision medicine, AI‑enabled discovery, and pragmatic real‑world trials, clinician participation across all practice settings will be increasingly necessary and essential.

  • Open Access

    Data and Safety Monitoring Board Best Practices in Clinical Trials

    by Gerald L Klein, Roger E Morgan, Melissa Palmer, Jamie Lazar, Freddy Byrth, Wayne M Dankner, Jamison Chang, John Hinkle, Jim Sergi

    A Data and Safety Monitoring Board (DSMB), also referred to as a Data Monitoring Committee (DMC), plays a critical role in safeguarding participant safety and ensuring the integrity of clinical trials. This article provides a narrative overview of best practices in DSMB structure, governance, and operations, informed by regulatory guidance from the U.S. Food and Drug Administration (FDA), National Institutes of Health (NIH), European Medicines Agency (EMA), and selected literature, as well as practical experience in clinical trial oversight. Key domains addressed include DSMB composition and independence, charter development and governance, data access and integrity, safety monitoring processes, interim analyses and adaptive decision-making, confidentiality, and sponsor responsibilities. The article also discusses common operational challenges and mitigation strategies, along with emerging trends such as Bayesian monitoring approaches and decentralized trial oversight. Rather than prescribing specific statistical thresholds, the manuscript emphasizes principles for maintaining scientific rigor, ethical oversight, and regulatory alignment. This overview is intended to support sponsors, Clinical Research Organizations (CROs), and DSMB members in implementing effective and compliant safety monitoring practices across a range of clinical trial settings.

  • Open Access

    The Essential Role of Medical Monitors in Clinical Trials

    by Gerald L. Klein, Elizabeth Barabash, Roger E Morgan, Gail Brown, Mark Tulchinskiy, Freddy Byrth, Emilia Jones Amaowei, Pavle Vukojevic, Shabnam Vaezzadeh, Katie-Louise Dawson, et al.

    Medical monitors (MMs) play a critical and often underrecognized role in ensuring patient safety, regulatory compliance, and scientific integrity during clinical trials. Particularly in early-stage pharma, biotechnology, and medical device development, the MM serves as an independent safeguard against bias and unanticipated risks. This editorial outlines the rationale, responsibilities, and operational value of the MM role, emphasizing its function in document review, real-time safety oversight, and regulatory alignment. Through illustrative case studies and current best practices, we argue that the independence and objectivity of the MM is a strategic business necessity, not merely a regulatory checkbox.

  • Open Access

    Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic

    by Ilham M. Alshiraihi, Gerald L. Klein, Mark A. Brown

    With the approval and distribution of demonstrably safe COVID-19 vaccines bearing exceptionally high efficacy profiles, it may be tempting to envision a return to “normal” in the coming months. However, if there is one lesson to be learned from the ongoing pandemic, it is that, in a world of evolving zoonotic viruses, we must be better prepared for the next deadly outbreak. While the acute nature of the COVID-19 pandemic demanded a highly specific approach, it is advisable to consider the breadth of seemingly endless possibilities in our approach to managing the next inevitable occurrence of an outbreak. Though there is little chance of discovering a “magic pill” to combat all future pathogens, the highly conserved nature of non-surface viral proteins exposes an “Achilles’ heel” in the structural genome of viral pathogens. Herein, we consider the potential of targeting such proteins to develop broad-spectrum therapeutics for the future. To illustrate this point, we outline the therapeutic potential of targeting the nonstructural protein 16 methyltransferase, which is conserved across most coronaviruses.